Results 251 to 260 of about 161,851 (302)

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants

New England Journal of Medicine, 2023
BACKGROUND The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab on hospitalizations for respiratory syncytial virus (RSV)-associated lower respiratory tract infection when administered in healthy infants are unclear. METHODS In
Simon B Drysdale, Mathieu Bangert, Pierre Tissieres   +2 more
exaly   +2 more sources

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

New England Journal of Medicine, 2020
BACKGROUND Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants.
Yuan Yuan, Joseph B Domachowske, Shabir A Madhi   +2 more
exaly   +2 more sources

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

Nature Medicine, 2023
The prolonged persistence at elevated levels of nirsevimab, an RSV-specific monoclonal antibody, likely accounts for the observed protection from severe disease throughout an RSV season, while it does not prevent the induction of a natural immune ...
Deidre Wilkins, Yuan Yuan, Yue Chang
exaly   +2 more sources

A condensate-hardening drug blocks RSV replication in vivo

Nature, 2021
Jennifer Risso-Ballester, Marie Galloux, Ronan Le Goffic   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Evaluating an RSV inhibitor

Nature Reviews Microbiology, 2022
exaly   +3 more sources

Delayed Seasonal RSV Surge Observed During the COVID-19 Pandemic

Pediatrics, 2021
An unexpected positive outcome of the coronavirus disease 2019 pandemic has been the marked decline in illness associated with other respiratory viruses, likely due to the widespread use of masks and social distancing.
R. Agha, J. Avner
semanticscholar   +1 more source

RSV through the COVID‐19 pandemic: Burden, shifting epidemiology, and implications for the future

Pediatric Pulmonology, 2023
Respiratory syncytial virus (RSV) represents a major global healthcare burden, particularly in those under 5 years of age. There is no available vaccine, with treatment limited to supportive care or palivizumab for high‐risk children.
R. Stein, H. Zar
semanticscholar   +1 more source

RSV Epidemiology in Australia Before and During COVID-19.

Pediatrics, 2022
BACKGROUND AND OBJECTIVES COVID-19 public health measures have altered respiratory syncytial virus (RSV) epidemiology, resulting in an unseasonal summer epidemic in Australia in 2020.
G. Saravanos, Nan Hu, N. Homaira, D. Muscatello, A. Jaffe, A. Bartlett, N. Wood, W. Rawlinson, A. Kesson, R. Lingam, P. Britton   +10 more
semanticscholar   +1 more source

Nirsevimab and Hospitalization for RSV Bronchiolitis

New England Journal of Medicine
BACKGROUND Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody against RSV that has an extended half-life.
Robert Cohen, Camille Jung, Harriet Corvol   +2 more
exaly   +2 more sources

Development of mRNA vaccines against respiratory syncytial virus (RSV).

Cytokine & growth factor reviews, 2022
Respiratory syncytial virus (RSV) is a single-stranded negative-sense RNA virus that is the primary etiologic pathogen of bronchitis and pneumonia in infants and the elderly. Currently, no preventative vaccine has been approved for RSV infection. However,
Xirui Qiu, Siyan Xu, Yang Lu, Zichen Luo, Yangtian Yan, Chuyue Wang, Jianjian Ji   +6 more
semanticscholar   +1 more source